Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics

References

• Adjei IM, and Blanka S. Modulation of the Tumor Microenvironment for Cancer Treatment: A Biomaterials Approach. J Funct Biomater. 2015;6(1):81–103. doi:10.3390/jfb6010081.
   PubMed Web of Science ®Google Scholar
• Ahuja N, Sharma AR, Baylin SB. Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med. 2016;67:73–89. doi:10.1146/annurev-med-111314-035900.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846–53. doi:10.1038/nm.3915.
   PubMed Web of Science ®Google Scholar
• Andreuzzi E, Colladel R, Pellicani R, Tarticchio G, Cannizzaro R, Spessotto P, Bussolati B, Brossa A, De Paoli P, Canzonieri V, Iozzo RV, Colombatti A, Mongiat M. The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis. Matrix Biol. 2017. doi: 10.1016/j.matbio.2017.04.002.
   Google Scholar
• Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32(3–4):623–42. doi:10.1007/s10555-013-9441-9.
   PubMed Web of Science ®Google Scholar
• Bar I, Merhi A, Abdel-Sater F, Ben Addi A, Sollennita S, Canon JL, Delrée P. The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer. J Histochem Cytochem. 2017;65(6):335–346. doi:10.1369/0022155417702849.
   PubMed Web of Science ®Google Scholar
• Berti FC, Pereira AP, Cebinelli GC, Trugilo KP, Brajão de Oliveira K. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev. 2017;34:1–13. doi:10.1016/j.cytogfr.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function”. Curr. Opin. Cell Biol. 2002;14(5): 608–16. doi:10.1016/S0955-0674(02)00361-7.
   PubMed Web of Science ®Google Scholar
• Bott A, Erdem N, Lerrer S, Hotz-Wagenblatt A, Breunig C, Abnaof K, Wörner A, Wilhelm H, Münstermann E, Ben-Baruch A, Wiemann S. miRNA-1246 induces pro-inflammatory responses in mesenchymal stem/stromal cells by regulating PKA and PP2A. Oncotarget. 2017;8(27):43897–43914.
   PubMed Web of Science ®Google Scholar
• Braicu C, Tomuleasa C, Monroig P, Cucuianu A, Berindan-Neagoe I, Calin GA. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 2015;22(1):34–45. doi:10.1038/cdd.2014.130.
   PubMed Web of Science ®Google Scholar
• Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–45. doi:10.1038/nature12625.
   PubMed Web of Science ®Google Scholar
• Campanella C, D'Anneo A, Marino Gammazza A, Caruso Bavisotto C, Barone R, Emanuele S. The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells. Oncotarget. 2016;7(20):28849–67. doi:10.18632/oncotarget.6680.
   PubMed Web of Science ®Google Scholar
• Cao Y, Huang H, Wang Z, Zhang G. The Inflammatory CXC Chemokines, GROαhigh, IP-10low, and MIGlow, in Tumor Microenvironment Can Be Used as New Indicators for Non-small Cell Lung Cancer Progression. Immunol Invest. 2017;46(4):361–374. doi:10.1080/08820139.2017.1280052.
   PubMed Web of Science ®Google Scholar
• Carmona-Fontaine C, Deforet M, Akkari L, Thompson CB, Joyce JA, Xavier JB. Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci U S A. 2017;114(11):2934–2939. doi:10.1073/pnas.1700600114.
   PubMed Web of Science ®Google Scholar
• Caruso Bavisotto C, Cappello F, Macario AJ, Conway de Macario E, Logozzi M4, Fais S. Exosomal HSP60: a potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment. Expert Rev Mol Diagn. 2017;17(9):815–822. doi:10.1080/14737159.2017.1356230.
   PubMed Web of Science ®Google Scholar
• Ceppi P, Peter ME. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene. 2014;33(3):269–78. doi:10.1038/onc.2013.55.
   PubMed Web of Science ®Google Scholar
• Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T. et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015;107(7). doi:10.1093/jnci/djv135.
   PubMedGoogle Scholar
• Chen Y, Huang S, Wu B, Fang J, Zhu M, Sun L, Zhang L, Zhang Y, Sun M, Guo L, Wang S. Transforming growth factor-β1 promotes breast cancer metastasis by downregulating miR-196a-3p expression. Oncotarget. 2017;8(30):49110–49122.
   PubMed Web of Science ®Google Scholar
• Chin L, Xia Y, Discher DE, Janmey PA. Mechanotransduction in cancer. Curr Opin Chem Eng. 2016;11:77–84. doi:10.1016/j.coche.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee JY, Suh JS, Park YS, Chung CP, Park YJ. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis. Int J Nanomedicine. 2016;11:4643–4656. doi:10.2147/IJN.S115044.
   PubMed Web of Science ®Google Scholar
• Chugh PE, Sin SH, Ozgur S, Henry DH, Menezes P, Griffith J. et al. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog. 2013;9(7):e1003484. doi:10.1371/journal.ppat.1003484.
   PubMed Web of Science ®Google Scholar
• Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol. 2014;20(7):1667–80. doi:10.3748/wjg.v20.i7.1667.
   PubMed Web of Science ®Google Scholar
• Cretu A, Brooks PC. Impact of the non-cellular tumor microenvironment on metastasis: potential therapeutic and imaging opportunities. J Cell Physiol. 2007;213(2). 391–402. doi:10.1002/jcp.21222.
   PubMed Web of Science ®Google Scholar
• Davidi S, Fremder E, Kan T, Raviv Z, Timaner M, Karin N, Hershkovitz D, Arohneim A, Shaked Y. The antiangiogenic role of the pro-inflammatory cytokine interleukin-31. Oncotarget. 2017;8(10):16430–16444.
   PubMed Web of Science ®Google Scholar
• Dejima H, Iinuma H, Kanaoka R, Matsutani N, Kawamura M. Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 2017;13(3):1256–1263.
   PubMed Web of Science ®Google Scholar
• Devashree J, Purohit S, Jain A, Sharma NK. Export of short RNAs: A bridge between breast carcinoma and their neighboring cells”. Front. Oncol. 2016;6:147.
   PubMed Web of Science ®Google Scholar
• Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4(1):11–22. doi:10.1038/nrc1252.
   PubMed Web of Science ®Google Scholar
• Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–27. doi:10.1016/j.molcel.2014.05.015.
   PubMed Web of Science ®Google Scholar
• Eichmüller SB, Osen W, Mandelboim O, Seliger B. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape. J Natl Cancer Inst. 2017;109(10).
   PubMedGoogle Scholar
• Evans-Knowell A, LaRue AC, Findlay VJ. MicroRNAs and Their Impact on Breast Cancer, the Tumor Microenvironment, and Disparities. Adv Cancer Res. 2017;133:51–76. doi:10.1093/jnci/djx034.
   PubMed Web of Science ®Google Scholar
• Fernandes JV, Cobucci RN, Jatobá CA, Fernandes TA, de Azevedo JW, de Araújo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015;21(3):527–34. doi:10.1007/s12253-015-9913-z.
   PubMed Web of Science ®Google Scholar
• Salazar-Onfray F, López MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007;18(1-2):171–82. doi:10.1016/j.cytogfr.2007.01.015.
   PubMed Web of Science ®Google Scholar
• Flower KJ, Ghaem-Maghami S, Brown R. Is there a role for epigenetic enhancement of immunomodulatory approaches to cancer treatment? Curr Cancer Drug Targets. 2017 doi: 10.2174/1568009617666170206105131.
   PubMed Web of Science ®Google Scholar
• Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, Sperduti I, Di Franco S, Meraviglia S, Lo Presti E, Dieli F, Caputo V, Militello G, Vieni S, Stassi G, Todaro M. IL-4 primes the dynamics of breast cancer progression via DUSP4 inhibition. Cancer Res. 2017;77(12):3268–3279. doi:10.1158/0008-5472.CAN-16-3126.
   PubMed Web of Science ®Google Scholar
• Gandellini P, Doldi V, Zaffaroni N. microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Semin Cancer Biol. 2017;44:132–140. doi:10.1016/j.semcancer.2017.03.005.
   PubMed Web of Science ®Google Scholar
• Gkretsi V, Stylianou A, Papageorgis P, Polydorou C, Stylianopoulos T. Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy. Frontiers in Oncology. 2015;5:214. doi:10.3389/fonc.2015.00214.
   PubMed Web of Science ®Google Scholar
• Goncearenco A, Rager SL, Li M, Sang QX, Rogozin IB, Panchenko AR. Exploring background mutational processes to decipher cancer genetic heterogeneity. Nucleic Acids Res. 2017. doi: 10.1093/nar/gkx367.
   PubMed Web of Science ®Google Scholar
• Goswami S, Sharma-Walia N. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis. Oncotarget. 2016;7(37):58953–58974. doi:10.18632/oncotarget.9835.
   PubMed Web of Science ®Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53. 615–627. doi:10.1146/annurev.med.53.082901.103929.
   PubMed Web of Science ®Google Scholar
• Gu DN, Jiang MJ, Mei Z, Dai JJ, Dai CY, Fang C, Huang Q, Tian L. microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression. Cancer Lett. 2017;400:69–78. doi:10.1016/j.canlet.2017.04.020.
   PubMed Web of Science ®Google Scholar
• Guo H, Zhu Q, Yu X, Merugu SB, Mangukiya HB, Smith N. et al. Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene. 2017;36(36):5098–5109. doi: 10.1038/onc.2017.132.
   Web of Science ®Google Scholar
• Güttlein LN, Benedetti LG, Fresno C, Spallanzani RG, Mansilla SF, Rotondaro C. et al. Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC. Mol Cancer Res. 2017;15(3):304–316.doi:10.1158/1541-7786.MCR-16-0243-T.
   PubMed Web of Science ®Google Scholar
• Halverson TWR, Wilton M, Poon KKH, Petri B, Lewenza S. DNA is an antimicrobial component of neutrophil extracellular traps. PLoS Pathog. 2015;11:e1004593. doi:10.1371/journal.ppat.1004593.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Harris NL, Vennin C, Conway JR, Vine KL, Pinese M, Cowley MJ, et al. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene. 2017;36(30):4288–4298. doi:10.1038/onc.2017.63.
   PubMed Web of Science ®Google Scholar
• Hawes MC, Wen F, Elquza E. Extracellular DNA: A Bridge to Cancer. Cancer Res. 2015;75(20):4260–4. doi:10.1158/0008-5472.CAN-15-1546.
   PubMed Web of Science ®Google Scholar
• He N, Feng G4, Li Y, Xu Y, Xie X, Wang H, et al. Embryonic stem cell preconditioned microenvironment suppresses tumorigenic properties in breast cancer. Stem Cell Res Ther. 2016;7(1):95. doi:10.1186/s13287-016-0360-x.
   PubMedGoogle Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26. doi:10.1038/nrc3599.
   PubMed Web of Science ®Google Scholar
• Hu R, Huffman KE, Chu M, Zhang Y, Minna JD, Yu Y. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer. J Proteome Res. 2016;15(2):477–86. doi:10.1021/acs.jproteome.5b00819.
   PubMed Web of Science ®Google Scholar
• Jia Y, Chen Y, Wang Q, Jayasinghe U, Luo X, Wei Q, Wang J, Xiong H, Chen C, Xu B, Hu W, Wang L, Zhao W, Zhou J. Exosome: emerging biomarker in breast cancer. Oncotarget. 2017;8(25):41717–41733.
   PubMed Web of Science ®Google Scholar
• Jiao C, Jiao X, Zhu A, Ge J, Xu X. Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma J Pediatr Surg. 2017;52(4):618–624. doi:10.1016/j.jpedsurg.2016.09.070.
   PubMed Web of Science ®Google Scholar
• Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets”. Nat Rev Drug Discov. 2011;10(12):945–63. doi:10.1038/nrd3599.
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. Discovery of Double-Stranded Genomic DNA in Circulating Exosomes. Cold Spring Harb Symp Quant Biol. 2017;81:275–280. doi:10.1101/sqb.2016.81.030932.
   Google Scholar
• Kalluri R, Zeisberg M. Fibroblast in cancer. Nat Rev Cancer. 2006;6(5):392–401. doi:10.1038/nrc1877.
   PubMed Web of Science ®Google Scholar
• Kenny PA, GY Lee, MJ Bissell. Targeting the tumor microenvironment. Front Biosci. 2007;(12):3468–3474. doi:10.2741/2327.
   PubMedGoogle Scholar
• Kinoshita T, Yip KW, Spence T, Liu FF. MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet. 2017;62(1):67–74. doi:10.1038/jhg.2016.87.
   PubMed Web of Science ®Google Scholar
• Koltai T Cancer: fundamentals behind pH targeting and the double-edged approach. Onco Targets Ther. 2016;9:6343–6360. doi:10.2147/OTT.S115438.
   PubMed Web of Science ®Google Scholar
• Konrad CV, Murali R, Varghese BA, Nair R. The role of cancer stem cells in tumor heterogeneity and resistance to therapy. Can J Physiol Pharmacol. 2017;95(1):1–15. doi:10.1139/cjpp-2016-0079.
   PubMed Web of Science ®Google Scholar
• Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer. 2013;4(1). 66–83. doi:10.7150/jca.5112.
   PubMed Web of Science ®Google Scholar
• Koren E, Fuchs Y. The bad seed: Cancer stem cells in tumor development and resistance. Drug Resist Updat. 2016;28:1–12. doi:10.1016/j.drup.2016.06.006.
   PubMed Web of Science ®Google Scholar
• Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–11572. doi:10.1007/s13277-016-5098-7.
   PubMedGoogle Scholar
• Li H, Fan X, and Houghton J. Tumor Microenvironment: The Role of the Tumor Stroma in Cancer. Journal of Cellular Biochemistry. 2007;101(4):805–815. doi:10.1002/jcb.21159.
   PubMed Web of Science ®Google Scholar
• Li SC, Vu LT, Luo JJ, Zhong JF, Li Z, Dethlefs BA, Loudon WG, Kabeer MH. Tissue elasticity bridges cancer stem cells to the tumor microenvironment through microRNAs: Implications for a “watch-and-wait” approach to cancer. Curr Stem Cell Res Ther. 2017;12(6):455–470. doi: 10.2174/1574888X12666170307105941.
   Web of Science ®Google Scholar
• Li Y, Cai B, Shen L, Dong Y, Lu Q, Sun S, Liu S, Ma S, Ma PX, Chen J. MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3. Cancer Lett. 2017;397:111–119. doi:10.1016/j.canlet.2017.03.032.
   PubMed Web of Science ®Google Scholar
• Li Y, Su J, Li F, Chen X, Zhang G. MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1α and VEGFA: Implications for psoriasis treatment. PLoS One. 2017;12(4):e0175459. doi:10.1371/journal.pone.0175459.
   PubMed Web of Science ®Google Scholar
• Lima CR, Gomes CC, Santos MF. Role of microRNAs in endocrine cancer metastasis. Mol Cell Endocrinol. 15(456):62–75. doi: 10.1016/j.mce.2017.03.015.
   Web of Science ®Google Scholar
• Lindeman GJ, Visvader JE. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer.2008;8(10):755–768. doi:10.1038/nrc2499.
   PubMed Web of Science ®Google Scholar
• Liotta LA, Kohn E. Anoikis: cancer and the homeless cell. Nature. 2004;430(7003):973–974. doi:10.1038/430973a.
   PubMed Web of Science ®Google Scholar
• Liu R, Liu C, Zhang D, Liu B, Chen X, Rycaj K, Jeter C, Calhoun-Davis T, Li Y, Yang T, Wang J, Tang DG. MiR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells. Oncotarget. 2016;7(35):56628–56642. doi:10.18632/oncotarget.10652.
   PubMed Web of Science ®Google Scholar
• Lobb RJ, Lima LG, Möller A. Exosomes: Key mediators of metastasis and pre-metastatic niche formation. Semin Cell Dev Biol. 2017;67:3–10. doi:10.1016/j.semcdb.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, et al. Extracellular metabolic energetics can promote cancer progression. Cell. 2015;160(3):393–406. doi:10.1016/j.cell.2014.12.018.
   PubMed Web of Science ®Google Scholar
• Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395–406. doi:10.1083/jcb.201102147.
   PubMed Web of Science ®Google Scholar
• Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–34. doi:10.1038/nrc3261.
   PubMed Web of Science ®Google Scholar
• Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105–17.
   PubMed Web of Science ®Google Scholar
• Mazor T, Pankov A, Song JS, Costello JF. Intratumoral Heterogeneity of the Epigenome. Cancer Cell. 2016;29(4):440–51. doi:10.1016/j.ccell.2016.03.009.
   PubMed Web of Science ®Google Scholar
• Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328–37. doi:10.1038/nature12624.
   PubMed Web of Science ®Google Scholar
• Meehan K, Vella LJ. The contribution of tumour-derived exosomes to the hallmarks of cancer. Crit Rev Clin Lab Sci. 2016;53(2):121–31. doi:10.3109/10408363.2015.1092496.
   PubMed Web of Science ®Google Scholar
• Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015;14(Suppl 4):19–31.
   PubMedGoogle Scholar
• Muscella A, Vetrugno C, Marsigliante S. CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture. Mol Carcinog. 2017;56(11):2461–2473. doi: 10.1002/mc.22693.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Nagahashi M, Rashid OM, Takabe K, Wakai T. The role of sphingosine-1-phosphate in the tumor microenvironment and its clinical implications. Tumour Biol. 2017;39(4):1010428317699133. doi:10.1177/1010428317699133.
   Google Scholar
• Nandhu MS, Kwiatkowska A, Bhaskaran V, Hayes J, Hu B, Viapiano MS. Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment. Oncogene. 2017;36(34):4875–4886. doi:10.1038/onc.2017.109.
   PubMed Web of Science ®Google Scholar
• Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, Bakal C, Yuan Y. Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. PLoS Med. 2016; 16;13(2):e1001961 doi:10.1371/journal.pmed.1001961.
   PubMed Web of Science ®Google Scholar
• Nie W, Yu T, Sang Y, Gao X. Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment. BiochemBiophys Res Commun. 2017;482(4):1400–1406. doi:10.1016/j.bbrc.2016.12.048.
   PubMed Web of Science ®Google Scholar
• Nilendu P, Kumar A, Kumar A, Pal JK, Sharma NK. Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack. International Journal of Cancer. 2017. DOI: 10.1002/ijc.30898.
   PubMed Web of Science ®Google Scholar
• Ortiz-Montero P, Londoño-Vallejo A, Vernot JP. Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun Signal. 2017;15(1):17. doi:10.1186/s12964-017-0172-3.
   PubMed Web of Science ®Google Scholar
• Owusu BY, Galemmo R, Janetka J, Klampfer L. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers (Basel). 2017;9(4). doi:10.3390/cancers9040035.
   PubMed Web of Science ®Google Scholar
• Pan Y, Smithson LJ, Ma Y, Hambardzumyan D, Gutmann DH. Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Oncotarget. 2017;8(20):32977–32989.
   PubMed Web of Science ®Google Scholar
• Park SA, Surh YJ. Modulation of tumor microenvironment by chemopreventive natural products. Ann N Y Acad Sci. 2017. doi: 10.1111/nyas.13395.
   PubMed Web of Science ®Google Scholar
• Patrice JM. The Microenvironment and Drug Resistance. Cancer Drug Resistance.2006;(2):201–210.
   Google Scholar
• Pautu V, Leonetti D, Lepeltier E, Clere N, Passirani C. Nanomedicine as a potent strategy in melanoma tumor microenvironment. Pharmacol Res. 2017;pii: S1043-6618(17):30015–4.
   Google Scholar
• Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788–799. doi:10.1038/nrc3603.
   PubMed Web of Science ®Google Scholar
• Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15(12):1243–53. doi:10.15252/embr.201439246.
   PubMed Web of Science ®Google Scholar
• Pike KA, Hui C, Krawczyk CM. Detecting Secreted Analytes from Immune Cells: An Overview of Technologies. Methods Mol Biol. 2016;1458:111–24. doi:10.1007/978-1-4939-3801-8_9.
   PubMedGoogle Scholar
• Kuninty Praneeth R, Schnittert Jonas, Storm Gert, and Prakash Jai. MicroRNA Targeting to Modulate Tumor Microenvironment. Front Oncol. 2016;6:3. doi:10.3389/fonc.2016.00003.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A. et al. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med. 2017;15(1):30. doi:10.1186/s12967-017-1134-7.
   PubMedGoogle Scholar
• Qin H, Ding Y, Mujeeb A, Zhao Y, Nie G. Tumor Microenvironment Targeting and Responsive Peptide-based Nano-formulations for Improved Tumor Therapy. Mol Pharmacol. 2017;92(3):219–231. doi:10.1124/mol.116.108084.
   PubMed Web of Science ®Google Scholar
• Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47–53. doi:10.1016/j.ceb.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Richard G, Brown N, Rouan F, Van der Schroeff JG, Bijlsma E, Eichenfield LF, et al.. Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. J Invest Dermatol. 2003;120(4):601–609. doi:10.1046/j.1523-1747.2003.12080.x.
   PubMed Web of Science ®Google Scholar
• Roberts DD. Emerging functions of matricellular proteins. Cell. Mol. Life Sci. 2011;68(19):3133–6. doi:10.1007/s00018-011-0779-2.
   PubMed Web of Science ®Google Scholar
• Romano G, Veneziano D, Acunzo M, Croce CM. Small non-Coding RNA and Cancer. Carcinogenesis. 2017;38(5):485–491. doi:10.1093/carcin/bgx026.
   PubMed Web of Science ®Google Scholar
• Rosner K, Kasprzak MF, Horenstein ACJ, Thurston HL, Abrams J, Kerwin LY, et al. Engineering a waste management enzyme to overcome cancer resistance to apoptosis: adding DNase1 to the anti-cancer toolbox. Cancer Gene Ther. 2011;18:346–57. doi:10.1038/cgt.2010.84.
   PubMed Web of Science ®Google Scholar
• Salimian Rizi B, Caneba C, Nowicka A, Nabiyar AW, Liu X, Chen K2. Nitric oxide mediates metabolic coupling of omentum-derived adipose stroma to ovarian and endometrial cancer cells. Cancer Res. 2015;75(2):456–71. doi:10.1158/0008-5472.CAN-14-1337.
   PubMed Web of Science ®Google Scholar
• Santangelo L, Battistelli C, Montaldo C, Citarella F, Strippoli R, Cicchini C. Functional Roles and Therapeutic Applications of Exosomes in Hepatocellular Carcinoma. Biomed Res Int. 2017;2017:2931813. doi:10.1155/2017/2931813.
   PubMedGoogle Scholar
• Seliger B. Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors. Cytokine Growth Factor Rev. 2017;36:49–56. doi:10.1016/j.cytogfr.2017.07.001.
   PubMed Web of Science ®Google Scholar
• Sharma SH, Thulasingam S, Nagarajan S. Chemopreventive agents targeting tumor microenvironment. Life Sci. 2016;145:74–84. doi:10.1016/j.lfs.2015.12.016.
   PubMed Web of Science ®Google Scholar
• Shintani Y, Fujiwara A, Kimura T, Kawamura T, Funaki S, Minami M, Okumura M. IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling. J Thorac Oncol. 2016;11(9):1482–92. doi:10.1016/j.jtho.2016.05.025.
   PubMed Web of Science ®Google Scholar
• Simmons AJ, Lau KS. Deciphering tumor heterogeneity from FFPE tissues: Its promise and challenges. Mol Cell Oncol. 2016;4(1):e1260191. doi:10.1080/23723556.2016.1260191.
   PubMed Web of Science ®Google Scholar
• Stadler S, Nguyen CH, Schachner H, Milovanovic D, Holzner S, Brenner S, Eichsteininger J. et al. Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling. Cell Mol Life Sci. 2017;74(10):1907–1921. doi:10.1007/s00018-016-2441-5.
   PubMed Web of Science ®Google Scholar
• Steinbichler TB, Dudás J, Riechelmann H, Skvortsova II. The Role of Exosomes in Cancer Metastasis. Semin Cancer Biol. 2017. doi: 10.1016/j.semcancer.2017.02.006.
   PubMed Web of Science ®Google Scholar
• Sung BH, Weaver AM. Exosome secretion promotes chemotaxis of cancer cells. Cell Adh Migr. 2017;11(2):187–195. doi:10.1080/19336918.2016.1273307.
   PubMed Web of Science ®Google Scholar
• Torres CM, Biran A, Burney MJ, Patel H, Henser-Brownhill T. et al. The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. Science. 2016;353(6307). doi:10.1126/science.aaf1644.
   PubMed Web of Science ®Google Scholar
• Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017;543(7643):122–125. doi:10.1038/nature21356.
   PubMed Web of Science ®Google Scholar
• Tzeng HT, Tsai CH, Yen YT, Cheng HC, Chen YC, et al. Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis. Clin Cancer Res. 2017;23(9):2335–2345. doi:10.1158/1078-0432.CCR-16-1520.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang D, Tian J, Gao A, Shen Y, Ren X, Li X, Jiang G, Dong T. Tumor necrosis factor receptor 2/AKT and ERK signaling pathways contribute to the switch from fibroblasts to CAFs by progranulin in microenvironment of colorectal cancer. Oncotarget. 2017;8(16):26323–26333.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen JQ, Liu JL, Tian L. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med. 2016; 19;14(1):297. doi:10.1186/s12967-016-1056-9.
   PubMedGoogle Scholar
• Wang Z, Tan Y, Yu W, Zheng S, Zhang S, Sun L, Ding K. Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells. Int J Biol Sci. 2017;13(3):339–348. doi:10.7150/ijbs.17680.
   PubMed Web of Science ®Google Scholar
• Wasmer MH, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol. 2017;7:682. doi:10.3389/fimmu.2016.00682.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Birzele F, Kollmorgen G, Rüger R. The Multiple Roles of Exosomes in Metastasis. Cancer Genomics Proteomics. 2017;14(1):1–15. doi:10.21873/cgp.20015.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Exosomes carrying immunoinhibitory proteins and their role in cancer. Clin Exp Immunol. 2017;189(3):259–267. doi:10.1111/cei.12974.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhuo L, Wang X. Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors. Semin Cell Dev Biol. 2017;64:125–131. doi:10.1016/j.semcdb.2016.11.003.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang X, Zhang B, Shi H, Yuan X, Sun Y, Pan Z, Qian H, Xu W. Exosomes derived from gastric cancer cells activate NF-κB pathway in macrophages to promote cancer progression. Tumour Biol. 2016;37(9):12169–12180. doi:10.1007/s13277-016-5071-5.
   PubMedGoogle Scholar
• Wu X, Chen X, Zhou Q, Li P, Yu B, Li J, Qu Y, Yan J, Yu Y, Yan M, Zhu Z, Liu B, Su L. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 2013;335(1):128–35. doi:10.1016/j.canlet.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Wyatt LC, Lewis JS, Andreev OA, Reshetnyak YK, Engelman DM. Applications of pHLIP Technology for Cancer Imaging and Therapy. Trends Biotechnol. 2017;35(7):653–664. doi:10.1016/j.tibtech.2017.03.014.
   PubMed Web of Science ®Google Scholar
• Yan J, Ma S, Zhang Y, Yin C, Zhou X, Zhang G. Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(35):e4644. doi:10.1097/MD.0000000000004644.
   PubMed Web of Science ®Google Scholar
• Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med. 2015;4(127):127ps10.
   Google Scholar
• Yuan Y. Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb Perspect Med. 2016;6(8): doi:10.1101/cshperspect.a026583.
   PubMed Web of Science ®Google Scholar
• Zhang H, Mai Q, Chen J. MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line. Cell Biol Int. 2017;41(3):267–275. doi:10.1002/cbin.10721.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang L, Cui M, Ye W, Zhang P, Zhou S. Wang J miR-302b inhibits cancer-related inflammation by targeting ERBB4, IRF2 and CXCR4 in esophageal cancer. Oncotarget. 2017;8(30):49053–49063.
   PubMed Web of Science ®Google Scholar
• Zou JM, Qin J, Li YC, Wang Y, Li D, Shu Y, Luo C, Wang SS, Chi G, Guo F, Zhang GM, Feng ZH. IL-35 induces N2 phenotype of neutrophils to promote tumor growth. Oncotarget. 2017;8(20):33501–33514.
   PubMed Web of Science ®Google Scholar